<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045405</url>
  </required_header>
  <id_info>
    <org_study_id>CDR132L-FIH01</org_study_id>
    <secondary_id>2019-001291-10</secondary_id>
    <nct_id>NCT04045405</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess Safety, PK and PD Parameters of CDR132L</brief_title>
  <official_title>Phase I, Randomized, Double-blind, Placebo-controlled Study to Assess Safety, PK and PD Parameters of CDR132L in Patients With Stable Heart Failure of Ischemic Origin (NYHA 1- 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardior Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardior Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, randomized, double-blind, placebo-controlled study to assess safety,
      pharmacokinetics and pharmacodynamic parameters of CDR132L in patients with stable heart
      failure of ischemic origin (NYHA 1-3).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      Primary

      • To assess the safety of one single and one repeated dose of CDR132L in patients with stable
      heart failure of ischemic origin (NYHA 1-3).

      Secondary • To characterize the pharmacokinetic (PK) profile of CDR132L in patients with
      stable heart failure of ischemic origin.

      Exploratory

      • To determine the effect of CDR132L on pharmacodynamic (PD) parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2019</start_date>
  <completion_date type="Actual">June 26, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events [safety and tolerability]</measure>
    <time_frame>4 months</time_frame>
    <description>The incidence and severity of treatment-emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>4 months</time_frame>
    <description>Pharmacokinetics parameter derived by non-compartmental methods to measure maximum observed plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>4 months</time_frame>
    <description>Pharmacokinetics parameter derived by non-compartmental methods to measure time to maximum plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC0-t)</measure>
    <time_frame>4 months</time_frame>
    <description>Pharmacokinetics parameter area under the plasma concentration-time curve from time zero to last detectable plasma concentration (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC0-inf)</measure>
    <time_frame>4 months</time_frame>
    <description>Pharmacokinetics parameter area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood clearance (CL)</measure>
    <time_frame>4 months</time_frame>
    <description>Pharmacokinetics parameter to determin clearance considering terminal elimination rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (t1/2)</measure>
    <time_frame>4 months</time_frame>
    <description>Pharmacokinetics parameter to determin half-life rate (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vdss)</measure>
    <time_frame>4 months</time_frame>
    <description>Pharmacokinetics parameter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CDR132L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDR132L</intervention_name>
    <description>i.v. administration</description>
    <arm_group_label>CDR132L</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable heart failure of ischemic origin

        Exclusion Criteria:

          -  Heart failure of non-ischemic origin (hypertensive heart disease, myocarditis,
             alcoholic cardiomyopathy and cardiac dysfunction due to rapid atrial fibrillation),
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried Hauke, MD MFPM</last_name>
    <role>Study Director</role>
    <affiliation>Cardior Pharmaceuticals GmbH CMO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorg Taubel, MD FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Pharmacology Ltd CEO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richmond Pharmacology Ltd., 1A Newcomen Street, London Bridge</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

